RTx-021 Clinical Trials (2026): 1 Studies for Stargardt Disease
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 RTx-021 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Stargardt Disease) and 18 total planned enrollment. 1 RTx-021 clinical trial is actively recruiting at 3 U.S. sites across 3 states. Most recent activity: NCT07439887 (Dec 2030).
Where to Participate: All RTx-021 Trial Sites in the U.S. (3 sites across 3 states)
Every actively recruiting RTx-021trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | RayTx Clinical Site | Bakersfield93309 | NCT07439887 | Map |
| PA | UPMC Vision Institute | Pittsburgh15219 | NCT07439887 | Map |
| TX | RayTx Clinical Site | Bellaire77401 | NCT07439887 | Map |
RTx-021 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1/P2 | 1 | 1 |
Recruiting RTx-021 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07439887 | AURORAPhase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease | P1/P2 | Stargardt Disease | 18 | Jan 2026 |
All RTx-021 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07439887 | AURORA | Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease | P1/P2 | recruiting | 18 | Ray Therapeutics, Inc. | Jan 2026 |
RTx-021 clinical trials: frequently asked questions
- How many RTx-021 clinical trials are there?
- 1 RTx-021 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are RTx-021 clinical trials recruiting in 2026?
- Yes — 1 RTx-021 trial is actively recruiting in 2026, with 3 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is RTx-021 being studied for?
- RTx-021 is being studied for Stargardt Disease. The trials are grouped by indication on this page.
- Who sponsors RTx-021 clinical trials?
- The lead sponsor across the most RTx-021 trials is Ray Therapeutics, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming RTx-021as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: